Fascaplysin as a specific inhibitor for cdk4: Insights from molecular modelling

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Shafiq, Muhammad Imtiaz ^a,b   Steinbrecher, Thomas ^c   Schmid, Ralf ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF THE PUNJAB   (Pakistan)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; FASCAPLYSIN; HISTIDINE; LYSINE;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME SPECIFICITY; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PROTEIN INTERACTION; STRUCTURAL HOMOLOGY; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CARBON; CATALYTIC DOMAIN; CELL CYCLE; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; HISTIDINE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LIGANDS; LYSINE; MODELS, CHEMICAL; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; THERMODYNAMICS;

EID: 84865057198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042612     Document Type: Article

References (86)

1. Harper JW, Adams PD, ((2001)) Cyclin-dependent kinases. Chem Rev 101:: 2511--2526.
2. Morgan D, ((1997)) Cyclin-dependent kinases: Engines, Clocks, and Microprocessors. Annual Review of Cell and Developmental Biology 13:: 261--291.
3. Morgan DO, ((1995)) Principles of CDK regulation. Nature 374:: 131--134.
4. Norbury C, Nurse P, ((1992)) Animal cell cycles and their control. Annual Review of Biochemistry 61:: 441--468.
5. Malumbres M, Barbacid M, ((2005)) Mammalian cyclin-dependent kinases. Trends in biochemical sciences 30:: 630--641.
6. Murray AW, ((2004)) Recycling the cell cycle: cyclins revisited. Cell 116:: 221--234.
7. Sherr CJ, ((1996)) Cancer Cell Cycles. Science 274:: 1672--1677.
8. Dyson N, ((1998)) The regulation of E2F by pRB-family proteins. Genes Dev 12:: 2245--2262.
9. Attwooll C, Lazzerini Denchi E, Helin K, ((2004)) The E2F family: specific functions and overlapping interests. EMBO J 23:: 4709--4716.
10. Malumbres M, Barbacid M, ((2001)) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:: 222--231.
11. Ortega S, Malumbres M, Barbacid M, ((2002)) Cell Cycle and Cancer: The G1 Restriction Point and the G1/S Transition. Current Genomics 3:: 245--263.
12. Malumbres M, Barbacid M, ((2006)) Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 9:: 2--4.
13. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, et al. ((2006)) Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9:: 23--32.
14. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW, ((2006)) Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9:: 13--22.
15. Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, et al. ((2006)) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95:: 185--194.
16. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O, ((2011)) Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 226:: 341--349.
17. Lapenna S, Giordano A, ((2009)) Cell cycle kinases as therapeutic targets for cancer. Nature Reviews Drug Discovery 8:: 547--566.
18. Malumbres M, Pevarello P, Barbacid M, Bischoff JR, ((2008)) CDK inhibitors in cancer therapy: what is next? Trends in Pharmacological Sciences 29:: 16--21.
19. McInnes C, ((2008)) Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discovery Today 13:: 875--881.
20. Lin TS, Fischer B, Blum KA, Andritsos LA, Jones JA, et al. ((2007)) Preliminary results of a phase II study of flavopiridol (Alvocidib) in, relapsed chronic lymphocytic leukemia (CLL): Confirmation of clinical activity in high-risk patients and achievement of complete responses (CR). Blood 110:: 913a--913a.
21. Lin TS, Heerema NA, Lozanski G, Fischer B, Blum KA, et al. ((2008)) Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities. Blood 112:: 23--24.
22. Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, et al. ((2009)) A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology 9:: 404--409.
23. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, et al. ((2005)) In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 16:: 1169--1176.
24. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. ((2007)) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:: 297--315.
25. Davies SP, Reddy H, Caivano M, Cohen P, ((2000)) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:: 95--105.
26. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, et al. ((2009)) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11:: R77.
27. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, et al. ((2004)) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:: 1427--1438.
28. Schwartz GK, Lorusso PM, Dickson MA, Randolph SS, Shaik MN, et al. ((2011)) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104:: 1862--1868.
29. Finn RS, ((2011)) A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. J Clin Oncol 29:suppl; abst TPS100.
30. Roll DM, Ireland CM, Lu HSM, Clardy J, ((1988)) Fascaplysin, an unusual antimicrobial pigment from the marine sponge Fascaplysinopsis sp. J Org Chem 53:: 3276--3278.
31. Jenkins PR, Wilson J, Emmerson D, Garcia MD, Smith MR, et al. ((2008)) Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorganic & Medicinal Chemistry 16:: 7728--7739.
32. Aubry C, Jenkins PR, Mahale S, Chaudhuri B, Marechal JD, et al. ((2004)) New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity. Chemical Communications pp. 1696--1697.
33. García MD, Wilson AJ, Emmerson DPG, Jenkins PR, Mahale S, et al. ((2006)) Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors. Organic & Biomolecular Chemistry 4:: 4478--4484.
34. Aubry C, Wilson AJ, Jenkins PR, Mahale S, Chaudhuri B, et al. ((2006)) Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin. Organic & Biomolecular Chemistry 4:: 787--801.
35. Mahale S, Aubry C, James Wilson A, Jenkins PR, Maréchal J-D, et al. ((2006)) CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. Bioorganic & Medicinal Chemistry Letters 16:: 4272--4278.
36. Mahale S, Aubry C, Jenkins PR, Maréchal J-D, Sutcliffe MJ, et al. ((2006)) Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin. Bioorg Chem 34:: 287--297.
37. Aubry C, Wilson AJ, Emmerson D, Murphy E, Chan YY, et al. ((2009)) Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1. Bioorganic & Medicinal Chemistry 17:: 6073--6084.
38. Day PJ, Cleasby A, Tickle IJ, O'Reilly M, Coyle JE, et al. ((2009)) Crystal structure of human CDK4 in complex with a D-type cyclin. Proceedings of the National Academy of Sciences 106:: 4166--4170.
39. Takaki T, Echalier A, Brown NR, Hunt T, Endicott JA, et al. ((2009)) The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proceedings of the National Academy of Sciences 106:: 4171--4176.
40. McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, et al. ((2004)) Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chemistry & Biology 11:: 525--534.
41. Mascarenhas NM, Bhattacharyya D, Ghoshal N, ((2010)) Why pyridine containing pyrido[2,3-d]pyrimidin-7-ones selectively inhibit CDK4 than CDK2: insights from molecular dynamics simulation. J Mol Graph Model 28:: 695--706.
42. Reddy MR, Erion MD, Agarwal A, ((2000)) Free energy calculations: Use and limitations in predicting ligand binding affinities. Reviews in Computational Chemistry, Vol 16 16:: 217--304.
43. Wang W, Donini O, Reyes CM, Kollman PA, ((2001)) Biomolecular simulations: Recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annual Review of Biophysics and Biomolecular Structure 30:: 211--243.
44. Lazaridis T, ((2002)) Binding affinity and specificity from computational studies. Current Organic Chemistry 6:: 1319--1332.
45. Simonson T, Archontis G, Karplus M, ((2002)) Free energy simulations come of age: Protein-ligand recognition. Accounts of Chemical Research 35:: 430--437.
46. Foloppe N, Hubbard R, ((2006)) Towards predictive ligand design with free-energy based computational methods? Current Medicinal Chemistry 13:: 3583--3608.
47. Jorgensen W, Thomas L, ((2008)) Perspective on free energy perturbation calculations for chemical equilibria. Journal of Chemical Theory and Computation 4:: 869--876.
48. Steinbrecher T, Labahn A, ((2010)) Towards Accurate Free Energy Calculations in Ligand Protein-Binding Studies. Current Medicinal Chemistry 17:: 767--785.
49. Chipot C, Rozanska X, Dixit SB, ((2005)) Can free energy calculations be fast and accurate at the same time? Binding of low-affinity, non-peptide inhibitors to the SH2 domain of the src protein. Journal of Computer-Aided Molecular Design 19:: 765--770.
50. Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A, Anderson KS, et al. ((2006)) Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic & Medicinal Chemistry Letters 16:: 663--667.
51. Kim JT, Hamilton AD, Bailey CM, Domoal RA, Wang L, et al. ((2006)) FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. Journal of the American Chemical Society 128:: 15372--15373.
52. Steinbrecher T, Case DA, Labahn A, ((2006)) A multistep approach to structure-based drug design: Studying ligand binding at the human neutrophil elastase. Journal of Medicinal Chemistry 49:: 1837--1844.
53. Steinbrecher T, Hrenn A, Dormann KL, Merfort I, Labahn A, ((2008)) Bornyl (3,4,5-trihydroxy)-cinnamate-an optimized human neutrophil elastase inhibitor designed by free energy calculations. Bioorganic & medicinal chemistry 16:: 2385--2390.
54. Zeevaart JG, Wang L, Thakur VV, Leung CS, Tirado-Rives J, et al. ((2008)) Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. Journal of the American Chemical Society 130:: 9492--9499.
55. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, et al. ((1995)) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:: 313--320.
56. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, et al. ((2000)) Comparative protein structure modeling of genes and genomes. Annual Review of Biophysics and Biomolecular Structure 29:: 291--325.
57. Wiederstein M, Sippl MJ, ((2007)) ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research 35:: W407--W410.
58. Hooft RWW, Vriend G, Sander C, Abola EE, ((1996)) Errors in protein structures. Nature 381:: 272--272.
59. Hypercube Inc (2008) HyperChem(TM) Professional 8.014 Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA.
60. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD, ((2003)) Improved protein-ligand docking using GOLD. Proteins 52:: 609--623.
61. DeLano WL (2002) The PyMOL Molecular Graphics System DeLano Scientific, Palo Alto, CA, USA.
62. Humphrey W, Dalke A, Schulten K, ((1996)) VMD: Visual molecular dynamics. Journal of Molecular Graphics 14:: 33--38.
63. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, et al. ((2005)) The Amber biomolecular simulation programs. Journal of Computational Chemistry 26:: 1668--1688.
64. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, et al. ((2003)) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24:: 1999--2012.
65. Wang JM, Wolf RM, Caldwell JW, Kollman PA, Case DA, ((2004)) Development and testing of a general amber force field. Journal of Computational Chemistry 25:: 1157--1174.
66. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA (2004) Gaussian 03, Revision B.03. Wallingford, CT 06492 USA: Gaussian, Inc.
67. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, ((1983)) Comparison of Simple Potential Functions for Simulating Liquid Water. Journal of Chemical Physics 79:: 926--935.
68. Horn HW, Swope WC, Pitera JW, Madura JD, Dick TJ, et al. ((2004)) Development of an improved four-site water model for biomolecular simulations: TIP4P-Ew. J Chem Phys 120:: 9665--9678.
69. Ryckaert JP, Ciccotti G, Berendsen HJC, ((1977)) Numerical-integration of cartesian equations of motion of a system with constraints- molecular- dynamics of n-alkanes. Journal of Computational Physics 23:: 327--341.
70. Gouda H, Kuntz ID, Case DA, Kollman PA, ((2003)) Free energy calculations for theophylline binding to an RNA aptamer: MM-PBSA and comparison of thermodynamic integration methods. Biopolymers 68:: 16--34.
71. Steinbrecher T, Mobley DL, Case DA, ((2007)) Nonlinear scaling schemes for Lennard-Jones interactions in free energy calculations. Journal of Chemical Physics 127:: 214108.
72. Darden T, Pearlman D, Pedersen LG, ((1998)) Ionic charging free energies: Spherical versus periodic boundary conditions. Journal of Chemical Physics 109:: 10921--10935.
73. Grossfield A, Ren PY, Ponder JW, ((2003)) Ion solvation thermodynamics from simulation with a polarizable force field. Journal of the American Chemical Society 125:: 15671--15682.
74. Steinbrecher T, Joung I, Case DA, ((2011)) Soft-Core Potentials in Thermodynamic Integration: Comparing One- and Two-Step Transformations. Journal of Computational Chemistry 32:: 3253--3263.
75. Rossi KA, Markwalder JA, Seitz SP, Chang CH, Cox S, et al. ((2005)) Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. Journal of Computer-Aided Molecular Design 19:: 111--122.
76. Tsou HR, Otteng M, Tran T, Floyd MB, Reich M, et al. ((2008)) 4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4). Journal of Medicinal Chemistry 51:: 3507--3525.
77. Mascarenhas NM, Ghoshal N, ((2008)) Combined ligand and structure based approaches for narrowing on the essential physicochemical characteristics for CDK4 inhibition. Journal of Chemical Information and Modeling 48:: 1325--1336.
78. Li AX, Barbault F, Maurel F, Delamar M, Wang BS, ((2008)) Interaction mode and selectivity of the 2PU inhibitor with the CDK4 and CDK2 cyclin-dependant kinases: A molecular dynamics study. Journal of Molecular Structure-Theochem 849:: 62--75.
79. Jiang YJ, Zou JW, Gui CS, ((2005)) Study of a ligand complexed with Cdk2/Cdk4 by computer simulation. Journal of Molecular Modeling 11:: 509--515.
80. Park H, Yeom MS, Lee S, ((2004)) Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: Comparative molecular dynamics simulation studies of CDK2 and CDK4. Chembiochem 5:: 1662--1672.
81. Buolamwini JK, ((2000)) Cell cycle molecular targets in novel anticancer drug discovery. Current Pharmaceutical Design 6:: 379--392.
82. Horiuchi T, Nagata M, Kitagawa M, Akahane K, Uoto K, ((2009)) Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2. Bioorg Med Chem 17:: 7850--7860.
83. Plewczynski D, Lazniewski M, Augustyniak R, Ginalski K, ((2011)) Can We Trust Docking Results? Evaluation of Seven Commonly Used Programs on PDBbind Database. Journal of Computational Chemistry 32:: 742--755.
84. Kellenberger E, Rodrigo J, Muller P, Rognan D, ((2004)) Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins-Structure Function and Bioinformatics 57:: 225--242.
85. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, et al. ((2006)) A critical assessment of docking programs and scoring functions. Journal of Medicinal Chemistry 49:: 5912--5931.
86. Shirts MR, Pitera JW, Swope WC, Pande VS, ((2003)) Extremely precise free energy calculations of amino acid side chain analogs: Comparison of common molecular mechanics force fields for proteins. Journal of Chemical Physics 119:: 5740--5761.